Dr. Reddy's Laboratories has launched Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg a therapeutic equivalent generic version of Vytorin (Ezetimibe and Simvastatin) Tablets in the United States market, approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's is among the first companies to launch the generic product in the U.S. market.
The Vytorin brand had U.S. sales of approximately USD 678 million MAT for the most recent twelve months ended in February 2017 according to IMS Health.
Dr. Reddy's Ezetimibe and Simvastatin Tablets are available in bottle count sizes of 30, 90 and 1000. Vytorin is a registered trademark of MSD International GmbH.
Shares of the company declined Rs 4.2, or 0.16%, to trade at Rs 2,606.85. The total volume of shares traded was 18,807 at the BSE (10.53 a.m., Thursday).